Burden of constipation-predominant irritable bowel syndrome (IBS-C) in France, Italy, and the United Kingdom

Clinical and Experimental Gastroenterology

Volumn 5, Issue 1, 2012, Pages 203-212

  DiBonaventura, Marco da Costa ^a   Prior, Mercedes ^b   Prieto, Pablo ^b   Fortea, Josep ^b  

^a KANTAR HEALTH   (United States)

^b Marketing and Medical Affairs ^*  (Spain)

Author keywords

Europe; Health care resource use; Health status; Work productivity

Indexed keywords

ABSENTEEISM; ADULT; ANXIETY DISORDER; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; FEMALE; FRANCE; FUNCTIONAL STATUS; HEALTH CARE UTILIZATION; HEALTH STATUS; HOSPITALIZATION; HUMAN; IRRITABLE COLON; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRODUCTIVITY; QUESTIONNAIRE; SHORT FORM 12; UNITED KINGDOM; WORK DISABILITY; WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE;

EID: 84869017221     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S35568     Document Type: Article

References (21)

1. Drossman DA, Chang L, Bellamy N, et al. Severity in irritable bowel syndrome: a Rome Foundation Working Team report. Am J Gastroenterol. 2011;106:1749-1759.
2. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003;17:643-650.
3. Gulewitsch MD, Enck P, Hautzinger M, Schlarb AA. Irritable bowel syndrome symptoms among German students: prevalence, characteristics, and associations to somatic complaints, sleep, quality of life, and childhood abdominal pain. Eur J Gastroenterol Hepatol. 2011;23:311-316.
4. Brun-Strang C, Dapoigny M, Lafuma A, Wainsten JP, Fagnani F. Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study. Eur J Gastroenterol Hepatol. 2007;19:1097-1103.
5. Akehurst RL, Brazier JE, Mathers N, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics. 2002;20:455-462.
6. Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics. 2006; 24:21-37.
7. Balboa A, Mearin F, Badía X, et al; RITMO Group. Impact of upper digestive symptoms in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2006;18:1271-1277.
8. Eriksson EM, Andrén KI, Eriksson HT, Kurlberg GK. Irritable bowel syndrome subtypes differ in body awareness, psychological symptoms and biochemical stress markers. World J Gastroenterol. 2008;14: 4889-4896.
9. Mönnikes H. Quality of life in patients with irritable bowel syndrome. J Clin Gastroenterol. 2011;45 Suppl:S98-S101.
10. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
11. Ware JE, Kosinski M, Turner-Bowker DM, Gandek B. How to Score Version 2 of the SF-12 Health Survey (with a supplement documenting version 1). Lincoln, RI: QualityMetric Incorporated; 2002.
12. Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med. 2001;33:350-357.
13. Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes. 2003;1:4.
14. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics. 1999;15:141-155.
15. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353-365.
16. DiBonaventura MD, Sun SX, Bolge SC, Wagner JS, Mody R. Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome. Curr Med Res Opin. 2011;27:2213-2222.
17. Naliboff BD, Kim SE, Bolus R, Bernstein CN, Mayer EA, Chang L. Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis. Am J Gastroenterol. 2012;107:451-459.
18. Moisan C, Eschwege E, Basdevant A, Charles M, DiBonaventura M, Bonnelye G. The epidemiology and burden of obesity and diabetes in France: a methodological comparison. Presented at the European Internal Society of Pharmacoeconomics and Outcomes Research Conference, Madrid, Spain, November 5-8, 2011.
19. Marrett E, DiBonaventura M, Zhang Q. Burden of illness associated with peripheral arterial disease in Europe. Presented at the European Internal Society of Pharmacoeconomics and Outcomes Research Conference, Madrid, Spain, November 5-8, 2011.
20. Bardin T, Khanna D, Perez-Ruiz F, et al. Quality of life, work impairment, and resource utilization associated with gout and its comorbidities across 5 EU countries: Results from the European National Health and Wellness Survey. Presented at the European League Against Rheumatism Conference, London, UK, May 25-28, 2011.
21. Kleinman L, Rentz A, Ciesla G, Kim JJ, Zacker C. Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther. 2002;24:675-689.